{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:13:19Z","timestamp":1780989199759,"version":"3.54.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"DOI":"10.3389\/fped.2019.00434","type":"journal-article","created":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T04:28:52Z","timestamp":1573014532000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["Conditioning Perspectives for Primary Immunodeficiency Stem Cell Transplants"],"prefix":"10.3389","volume":"7","author":[{"given":"Peter","family":"Shaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Shizuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Hoenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Veys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"IEWP-EBMT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,11,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1182\/blood-2012-03-417758","article-title":"Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for nonmalignant disorders","volume":"120","author":"Horan","year":"2012","journal-title":"Blood."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/S0140-6736(68)92673-1","article-title":"Immunological reconstitution of sex-linked lymphopenic immunological deficiency","volume":"2","author":"Gatti","year":"1968","journal-title":"Lancet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1056\/NEJM196909252811302","article-title":"Treatment of lymphopenic hypogammaglobulinemia and bone-marrow aplasia by transplantation of allogeneic marrow. Crucial role of histocompatiility matching","volume":"281","author":"Meuwissen","year":"1969","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S0140-6736(13)62069-3","article-title":"Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study","volume":"383","author":"Gungor","year":"2014","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1182\/bloodadvances.2018016956","article-title":"Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine","volume":"2","author":"Harris","year":"2018","journal-title":"Blood Adv"},{"key":"B7","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1182\/blood-2002-11-3615","article-title":"Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation","volume":"103","author":"Casper","year":"2004","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"15018","DOI":"10.1073\/pnas.1205858109","article-title":"Brain conditioning is instrumental for successful microglia reconstitution following hematopoietic stem cell transplantation","volume":"109","author":"Capotondo","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B9","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/mt.2013.29","article-title":"Busulfan conditioning enhances engraftment of hematopoietic donor-derived cells in the brain compared with irradiation","volume":"21","author":"Wilkinson","year":"2013","journal-title":"Mol Ther"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4367","DOI":"10.1182\/blood-2010-10-312082","article-title":"Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience","volume":"117","author":"Slatter","year":"2011","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1182\/blood-2016-03-704015","article-title":"Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience","volume":"128","author":"Morillo-Gutierrez","year":"2016","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.bbmt.2017.11.009","article-title":"Treosulfan and fludarabine conditioning for hematopoietic stem cell transplantation in children with primary immunodeficiency: UK experience","volume":"24","author":"Slatter","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.jaci.2017.07.008","article-title":"T-cell receptor \u03b1\u03b2+ and CD19+ cell\u2013depleted haploidentical and mismatched hematopoietic stem cell transplantation in primary immune deficiency","volume":"141","author":"Shah","year":"2018","journal-title":"J Allergy Clin Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood-2010-11-319376","article-title":"Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980\u20132009: an international collaborative study","volume":"118","author":"Moratto","year":"2011","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.jaci.2018.10.026","article-title":"Tregopathies: Monogenic diseases resulting in regulatory T-cell deficiency","volume":"142","author":"Cepika","year":"2018","journal-title":"J Allergy Clin Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1182\/blood-2004-03-0960","article-title":"Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen","volume":"105","author":"Rao","year":"2005","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.jaci.2016.01.053","article-title":"Effect of stem cell source on long-term chimerism and event-free survival in children with primary immunodeficiency disorders after fludarabine and melphalan conditioning regimen","volume":"138","author":"Rao","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.bbmt.2015.04.009","article-title":"Experience with alemtuzumab, fludarabine, and melphalan reduced-intensity conditioning hematopoietic cell transplantation in patients with nonmalignant diseases reveals good outcomes and that the risk of mixed chimerism depends on underlying disease, stem cell source, and alemtuzumab regimen","volume":"21","author":"Marsh","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"key":"B19","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1182\/blood.V61.2.341.bloodjournal612341","article-title":"Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells","volume":"61","author":"Reisner","year":"1983","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1182\/blood-2014-03-563817","article-title":"HLA-haploidentical stem cell transplantation after removal of alphabeta+ T and B cells in children with nonmalignant disorders","volume":"124","author":"Bertaina","year":"2014","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"E67","DOI":"10.3390\/biomedicines5040067","article-title":"The role of anti-thymocyte globulin or alemtuzumab-based serotherapy in the prophylaxis and management of graft-versus-host disease","volume":"5","author":"Ali","year":"2017","journal-title":"Biomedicines."},{"key":"B22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3389\/fimmu.2019.00315","article-title":"Differential elimination of anti-thymocyte globulin of fresenius and genzyme impacts T-cell reconstitution after hematopoietic stem cell transplantation","volume":"10","author":"Oostenbrink","year":"2019","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.bbmt.2014.11.674","article-title":"Impact of serotherapy on immune reconstitution and survival outcomes after stem cell transplantations in children: thymoglobulin versus alemtuzumab","volume":"21","author":"Willemsen","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B24","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1182\/blood-2013-05-502385","article-title":"Impact of thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome","volume":"123","author":"Lindemans","year":"2014","journal-title":"Blood."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1016\/S2352-3026(15)00045-9","article-title":"Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis","volume":"2","author":"Admiraal","year":"2015","journal-title":"Lancet Haematol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1182\/blood-2015-07-659672","article-title":"Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT","volume":"127","author":"Marsh","year":"2016","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.bbmt.2016.02.001","article-title":"Alternative-donor hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for nonmalignant disorders","volume":"22","author":"Klein","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1016\/j.bbmt.2019.05.005","article-title":"Gonadal function after busulfan compared with treosulfan in children and adolescents undergoing allogeneic hematopoietic stem cell transplant","volume":"25","author":"Faraci","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1182\/blood-2013-01-476432","article-title":"SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID","volume":"123","author":"Schuetz","year":"2014","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1182\/blood.V78.7.1864.1864","article-title":"Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque","volume":"78","author":"Matthews","year":"1991","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"351ra105","DOI":"10.1126\/scitranslmed.aae0501","article-title":"Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy","volume":"8","author":"Chhabra","year":"2016","journal-title":"Sci Transl Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1126\/science.1149726","article-title":"Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches","volume":"318","author":"Czechowicz","year":"2007","journal-title":"Science"},{"key":"B33","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1053\/bbmt.2003.50024","article-title":"Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy","volume":"9","author":"Krance","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"B34","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/S0140-6736(09)60945-4","article-title":"Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1\/2 study","volume":"374","author":"Straathof","year":"2009","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/2040620711422265","article-title":"Radiolabeled antibodies directed at CD45 for conditioning prior to allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome","volume":"3","author":"Orozco","year":"2012","journal-title":"Ther Adv Hematol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/nbt.3584","article-title":"Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin","volume":"34","author":"Palchaudhuri","year":"2016","journal-title":"Nat Biotechnol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41467-018-08201-x","article-title":"Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation","volume":"10","author":"Czechowicz","year":"2019","journal-title":"Nat Commun."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1182\/blood-2018-06-853879","article-title":"Anti-human CD117 antibody-mediated bone marrow niche clearance in non-human primates and humanized NSG mice","volume":"133","author":"Kwon","year":"2019","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1016\/j.bbmt.2018.12.172","article-title":"Toxicity-free hematopoietic stem cell engraftment achieved with anti-CD117 monoclonal antibody conditioning","volume":"25","author":"Agarwal","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"B40","doi-asserted-by":"publisher","first-page":"5419","DOI":"10.1182\/blood-2010-07-295949","article-title":"Antibody targeting KIT as pretransplantation conditioning in immunocompetent mice","volume":"116","author":"Xue","year":"2010","journal-title":"Blood"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fped.2019.00434\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T04:28:54Z","timestamp":1573014534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fped.2019.00434\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,6]]},"references-count":40,"alternative-id":["10.3389\/fped.2019.00434"],"URL":"https:\/\/doi.org\/10.3389\/fped.2019.00434","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,6]]},"article-number":"434"}}